SerbiaThe FDA has approved the first gene therapy for children aged two and older with sickle cell disease, marking a significant advancement in treating this life-threatening blood disorder. Sickle cell disease affects red blood cells, causing severe pain episodes known as vaso-occlusive crises. The new treatment, called Casgevy, uses the patient's own stem cells edited with CRISPR/Cas9 technology to increase fetal hemoglobin levels, which helps prevent the formation of abnormally shaped red blood cells. This therapy was previously approved for patients over 12 years old but now offers a critical additional option for younger pediatric patients. The approval highlights progress in addressing the genetic cause of the disease and improving long-term health outcomes for affected children.
Lettura del bias (Centro): The article focuses on medical advancements and does not present any political controversy, bias, or partisan framing. It provides factual information about a newly approved treatment without taking a stance or emphasizing any particular ideological perspective.
Perché questi punteggi (Fattualità 85 · Obiettività 75): The article accurately reports the FDA's approval of Casgevy for children aged 2 and older with sickle cell disease, aligning with the primary source. However, it lacks detailed information on the clinical trials and mechanisms of the therapy. The tone is somewhat promotional, focusing more on the s
